Farxiga (dapagliflozin) tablets

Farxiga, generically known as dapagliflozin, is a prescription medication primarily used to manage type 2 diabetes, heart failure, and chronic kidney disease. The brand was developed through a significant pharmaceutical collaboration between Bristol-Myers Squibb and AstraZeneca, marking a major milestone in endocrinology treatments following its initial global approvals in the early 2010s.

While the brand has its roots in a joint venture between American and British-Swedish pharmaceutical giants, AstraZeneca acquired Bristol-Myers Squibb's share of the diabetes alliance in 2014, becoming the sole owner. Today, the product is manufactured in several specialized pharmaceutical facilities across the globe, including sites in the United Kingdom, the United States, and Germany, to meet international demand regulated by local health authorities like the FDA.